80 results
8-K
EX-99.1
ZVRA
Zevra Therapeutics Inc
8 May 24
Zevra Therapeutics Reports First Quarter 2024 Financial Results and Corporate Updates
7:54am
statements regarding the potential benefits of our debt facility, our cash balance, our corporate governance objectives, potential revenues from our
DEFA14A
ZVRA
Zevra Therapeutics Inc
29 Apr 24
Additional proxy soliciting materials
7:49am
point of value creation.
We’re Committed to Governance Best Practices
From the beginning of 2023 through today, the composition of our Board … .
The newly composed Board immediately moved into action by affirming its commitment to employing governance best practices for a company of our size and stage
424B3
uy1dlgbkpw0q4zsl
10 Oct 23
Prospectus supplement
5:07pm
S-4/A
r4dcnhpa
6 Oct 23
Registration of securities issued in business combination transactions (amended)
4:06pm
S-4
jiu6v8im
28 Sep 23
Registration of securities issued in business combination transactions
9:25pm
425
9mz4dm8o 275m
31 Aug 23
Business combination disclosure
8:03am
8-K
EX-2.1
kfauh5 mbd65mr0
31 Aug 23
Zevra Therapeutics to Acquire Acer Therapeutics, Expanding its Rare Disease Portfolio and Adding Commercial Product
8:01am
424B3
80103
10 Nov 21
Prospectus supplement
5:19pm
424B3
vp3d4iq907bqv w7
19 Oct 21
Prospectus supplement
9:27am